Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat

May 11, 2015 10:57 AM EDT

Guggenheim reiterates their Buy rating on Actavis (NYSE: ACT), and raised the price target to $355.00 (from $345.00), following a 1Q15 beat. ACT reported an adjusted 1Q15 diluted EPS of $4.30. This came $0.34 higher than consensus, and $0.41 better than Guggenheim estimates.

Guggenheim analyst, Louise Chen,... More